Method and apparatus for bridging from a dressing in negative pressure wound therapy

Information

  • Patent Grant
  • RE46825
  • Patent Number
    RE46,825
  • Date Filed
    Thursday, April 24, 2014
    10 years ago
  • Date Issued
    Tuesday, May 8, 2018
    6 years ago
Abstract
A method of bridging from a wound dressing to a wound port for negative pressure wound therapy includes positioning an elongate wick between a wound and a remote location with respect to the wound. The elongate wick includes a three-dimensional spacer fabric having an upper fabric layer spaced from a lower fabric layer by an intermediate layer of pile threads. The elongate wick is covered with a flexible wick cover such that an enclosure is formed around the elongate wick. A substantially fluid-tight seal is established between a first end of the elongate wick cover and the wound dressing such that a reservoir is defined over the wound in which a negative pressure may be maintained. A substantially fluid-tight seal is established between a second end of the elongate wick cover and a fluid port configured for connection to a source of negative pressure.
Description
BACKGROUND

1. Technical Field


The present disclosure relates generally to treating a wound with negative or reduced pressure. In particular, the disclosure relates to a dressing for transporting fluids from a wound site to a fluid port in a remote location, and also a method for applying the dressing.


2. Background of Related Art


Various techniques to promote healing of a wound involve providing suction to the wound. For example, a vacuum source may serve to carry wound exudates away from the wound, which may otherwise harbor bacteria that inhibit the body's natural healing process. One particular technique for promoting the body's natural healing process may be described as negative pressure wound therapy (NPWT). This technique involves the application of a reduced pressure, e.g. sub-atmospheric, to a localized reservoir over a wound. Sub-atmospheric pressure has been found to assist in closing the wound by promoting blood flow to the area, thereby stimulating the formation of granulation tissue and the migration of healthy tissue over the wound. This technique has proven effective for chronic or non-healing wounds, but has also been used for other purposes such as post-operative wound care.


The general NPWT protocol provides for covering the wound with a flexible cover layer such as a polymeric film, for example, to establish a vacuum reservoir over the wound where a reduced pressure may be applied by individual or cyclic evacuation procedures. To allow the reduced pressure to be maintained over time, the cover layer may include an adhesive periphery that forms a substantially fluid tight seal with the healthy skin surrounding the wound.


Although some procedures may employ a micro-pump contained within the vacuum reservoir, most NPWT treatments apply a reduced pressure using an external vacuum source. Fluid communication must therefore be established between the reservoir and the vacuum source. To this end, a fluid port is often coupled to the cover layer to provide an interface for a fluid conduit extending from the external vacuum source. The fluid port typically exhibits a degree of rigidity, which provides for a convenient reception of the fluid conduit. The fluid port also may project somewhat from the surrounding skin, and may thus tend to cause discomfort for patients as the fluid port is inadvertently pressed into the wound. This tendency is particularly evident when a fluid port is used on wounds on a patient's back, heel or other locations where pressure points develop as the patient reclines or sits. Accordingly, it may be advantageous to position the fluid port at a location remote from the wound, and to draw fluid from the wound to the remotely positioned fluid port.


SUMMARY

A method of bridging from a wound dressing to a wound port for negative pressure wound therapy includes positioning an elongate wick between a wound and a remote location with respect to the wound wherein the elongate wick includes a three-dimensional spacer fabric. The three-dimensional spacer fabric defines an upper fabric layer and a lower fabric layer, wherein the upper fabric layer and the lower fabric layer are spaced from one another by an intermediate layer of pile threads. The elongate wick is covered with a flexible wick cover such that an enclosure is formed around the elongate wick. A substantially fluid-tight seal is established between a first end of the elongate wick cover and the wound dressing such that a reservoir is defined over the wound in which a negative pressure may be maintained. A substantially fluid-tight seal is established between a second end of the elongate wick cover and at least one of a fluid port, a fluid conduit and a source of negative pressure.


The method may also include positioning a skin covering between the wound and the remote location to substantially minimize contact of fluids with a skin surface adjacent the wound. The elongate skin covering may define a width of about 2 inches, the elongate wick may define a width of about 1 inch, and the wick cover may define a width of about 3 inches.


The method may also include the step of applying heat to the spacer fabric to conform the spacer fabric to a particular body contour. Also, the method may include the step of drawing fluids through the elongate wick.


According to another aspect of the disclosure, a composite wound dressing apparatus includes a cover layer for defining a reservoir over a wound in which a negative pressure may be maintained by forming a substantially fluid-tight seal around the wound. The cover layer includes an aperture therein through which fluids may be extracted from the reservoir. An elongate wick includes a first end in fluid communication with the reservoir through the aperture in the cover layer, and a second end disposed remotely with respect to the aperture in the cover layer. The elongate wick includes a three-dimensional spacer fabric. A flexible wick cover extends over the elongate wick. The wick cover has a first end configured for forming a substantially fluid tight seal over the aperture in the cover layer, and a second end including an aperture therein through which fluids may be extracted from the elongate wick. A fluid port is coupled to the wick cover and in fluid communication with the second end of the elongate wick through the aperture in the wick cover.


The apparatus may include a skin covering positioned beneath at least a portion of the elongate wick to substantially minimize contact of fluids with a skin surface adjacent the wound. The skin covering may define a first width, the wick cover may define a second width and the elongate wick may define a third width, wherein the third width of the wick cover is substantially greater than the first width of the skin covering. The first width may be about 2 inches, the second width may be about one inch, and the third width may be about 3 inches.


The fluid port may be configured to receive a fluid conduit, and may include a flange coupled to an underside of the wick cover. The elongate wick may be treated with an antimicrobial agent, and the antimicrobial agent may be polyhexamethylene biguanide.


According to another aspect of the disclosure, a negative pressure wound therapy apparatus includes a cover layer for defining a reservoir over a wound in which a negative pressure may be maintained by forming a substantially fluid-tight seal around the wound. The cover layer includes an aperture therein through which fluids may be extracted from the reservoir. The apparatus also includes an elongate wick having a first end and a second end, wherein the first end is in fluid communication with the reservoir through the aperture in the cover layer, and the second end is disposed remotely with respect to the aperture in the cover layer. The elongate wick includes a three-dimensional spacer fabric. Also, a flexible wick cover extends over the elongate wick and has a first end and a second end. The first end of the wick cover is configured for forming a substantially fluid tight seal over the aperture in the cover layer, and the second end includes an aperture through which fluids may be extracted from the elongate wick. A vacuum source is in fluid communication with the reservoir, and is suitable for generating the negative pressure in the reservoir.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the detailed description of the embodiments given below, serve to explain the principles of the disclosure.



FIG. 1A is a cross sectional view of an NPWT treatment apparatus including a fluid port in the vicinity of a vacuum reservoir for treating a wound;



FIG. 1B is a partial cross sectional view of the fluid port of FIG. 1A affixed in an alternate configuration;



FIG. 1C is a partial cross sectional view of the fluid port of FIG. 1A affixed in another alternate configuration;



FIG. 2A is a cross sectional view of a composite wound dressing and bridging dressing with the fluid port in a remote location in accordance with the present disclosure as applied on the wound;



FIG. 2B is a top view of the composite dressing and bridging dressing of FIG. 2A;



FIG. 3 is a close up perspective view of the elongate wick of FIG. 2A;



FIG. 4A is a partial cross-sectional view of an alternate configuration of a bridging dressing applied without a flanged fluid port; and



FIG. 4B is a partial cross sectional view of a bridging dressing coupled to a wound dressing in an alternate configuration.





DETAILED DESCRIPTION OF EMBODIMENTS

Referring initially to FIG. 1, an NPWT apparatus is depicted generally as 10 for use on a wound “w” surrounded by healthy skin “s.” The NPWT apparatus 10 includes a wound dressing 12 positioned relative to the wound “w” to define a reservoir 14 in which a negative pressure appropriate to stimulate healing may be maintained.


Wound dressing 12 includes a contact layer 18 positioned in direct contact with the bed of wound “w” and may be formed from perforated film material. An appropriate perforated material permits the negative pressure applied to the reservoir to penetrate into the wound “w,” and also permits exudates to be drawn through the contact layer 18. Passage of wound fluid through the contact layer 18 is preferably unidirectional such that exudates do not flow back into the wound bed. Unidirectional flow may be encouraged by conical or directional apertures formed in the contact layer 18, or a lamination of materials having absorption properties differing from those of contact layer 18. A non-adherent material may be selected such that contact layer 18 does not tend to cling to the wound “w” or surrounding tissue when it is removed. One exemplary material that may be used as a contact layer 18 is sold under the trademark XEROFORM®, CURITY®, and VENTEX® by Tyco Healthcare Group LP (d/b/a Covidien).


Wound filler 20 is positioned in the wound “w” over the contact layer 18 and is intended to allow wound dressing 12 to absorb, capture and/or wick wound exudates. Wound filler 20 is cut to a shape that is conformable to the shape of wound “w,” and may be packed up to the level of healthy skin “s,” or alternatively, wound filler 20 may overfill the wound “w.” An absorbent material such as non-woven gauze, reticulated foam, or alginate fibers may be used for filler 20 to transfer any exudate that migrates through contact layer 18 away from the wound “w”. An antimicrobial dressing sold under the trademark KERLIX® AMD by Tyco Healthcare Group LP (d/b/a Covidien), may be suitable for use as filler 20.


Wound dressing 12 also includes a cover layer 22. Cover layer 22 may be positioned over the wound “w” to form a substantially fluid-tight seal with the surrounding skin “s.” Thus, cover layer 22 may act as both a microbial barrier to prevent contaminants from entering the wound “w,” and also a fluid barrier maintaining the integrity of vacuum reservoir 14. Cover layer 22 is preferably formed from a moisture vapor permeable membrane to promote the exchange of oxygen and moisture between the wound “w” and the atmosphere, and is preferably transparent permit a visual assessment of wound conditions without requiring removal of the cover layer 22. A membrane that provides a sufficient moisture vapor transmission rate (MVTR) is a transparent membrane sold under the trade name POLYSKIN® II by Tyco Healthcare Group LP (d/b/a Covidien). Cover layer 22 includes an aperture 24 therein, through which wound fluids and atmospheric gasses may be removed from the dressing 12 under the influence of a reduced pressure.


A fluid port 30 having a flange 34 may also be included in wound dressing 12 to facilitate connection of the wound dressing 12 to fluid conduit 36. The fluid port 30 may be configured as a rigid or flexible, low-profile component, and may be adapted to receive a fluid conduit 36 in a releasable and fluid-tight manner. An adhesive on the underside of flange 34 may provide a mechanism for affixing the fluid port 30 to the dressing 12, or alternatively the flange 34 may be positioned within reservoir 14 (FIG. 1B) such that an adhesive on an upper side of the flange 34 affixes the fluid port 30. As depicted in FIG. 1C, an additional alternative for affixing the fluid port to the cover layer involves securing the flange 34 to the cover layer with a skirt 22a. The skirt 22a may be constructed of an adhesively coated polymeric film similar to the cover layer 22. However it is affixed to the dressing, a hollow interior of the fluid port 30 provides fluid communication between the fluid conduit 36 and the reservoir 14.


Fluid conduit 36 extends from the fluid port 30 to provide fluid communication between the reservoir 14 and collection canister 40. Any suitable conduit may be used for fluid conduit 36 including those fabricated from flexible elastomeric or polymeric materials. Fluid conduit 36 may connect components of the NPWT apparatus by conventional air-tight means such as friction fit, bayonet coupling, or barbed connectors. The conduit connections may be made permanent, or alternatively a quick-disconnect or other releasable means may be used to provide some adjustment flexibility to the apparatus 10.


Collection canister 40 may comprise any container suitable for containing wound fluids. For example, a rigid bottle may be used as shown or alternatively a flexible polymeric pouch may be appropriate. Collection canister 40 may contain an absorbent material to consolidate or contain the wound drainage or debris. For example, super absorbent polymers (SAP), silica gel, sodium polyacrylate, potassium polyacrylamide or related compounds may be provided within canister 40. At least a portion of canister 40 may be transparent to assist in evaluating the color, quality or quantity of wound exudates. A transparent canister may thus assist in determining the remaining capacity of the canister or when the canister should be replaced.


Leading from collection canister 40 is another section of fluid conduit 36 providing fluid communication with vacuum source 50. Vacuum source 50 generates or otherwise provides a negative pressure to the NPWT apparatus 10. Vacuum source 50 may comprise a peristaltic pump, a diaphragmatic pump or other mechanism that draws fluids, e.g. atmospheric gasses and wound exudates, from the reservoir 14 appropriate to stimulate healing of the wound “w.” Preferably, the vacuum source 50 is adapted to produce a sub-atmospheric pressure in the reservoir 14 ranging between about 20 mmHg and about 500 mm Hg, about 75 mm Hg to about 125 mm Hg, or, more preferably, between about 40 mm HG and 80 mm Hg.


Referring now to FIGS. 2A and 2B, a composite wound dressing 100 is depicted, which permits a fluid port 30 and the associated fluid conduit 36 to be located remotely with respect to the wound “w.” Composite wound dressing 100 includes a contact layer 18, a wound filler 20 and a cover layer 22 applied to the wound “w” in a manner similar to wound dressing 12 discussed above with reference to FIG. 1. The fluid port 30, however, is affixed to the composite wound dressing 100 at a location “r” that is remote from the wound “w,” rather than being affixed to the cover layer 22 at the aperture 24.


To provide fluid communication, or a “bridge,” between aperture 24 and the remote location “r,” a bridging dressing 102 is positioned partially over the cover layer 22 and partially over the healthy skin “s” to span the distance between the wound “w” and the remote location “r.” The remote location “r” may be an area of the healthy skin “s” where the fluid port 30 or the associated fluid conduit 36 will tend not to irritate the wound “w” or to cause discomfort for the patient. If the wound “w” is located on the back of a patient, the remote location “r” may be, for example, at the chest or shoulder of the patient. This permits the patient to lie comfortably without placing undue pressure on the fluid port 30. To provide this functionality, a bridging dressing 102 may exhibit a length in the range from about 4 inches to about 12 inches, or more.


The bridging dressing 102 includes a skin covering such as film or lining 103, an elongate wick 104, a wick cover 106, and the fluid port 30. The film or lining 103 will be placed in contact with skin, typically, the healthy skin along a portion of the “bridge.” The lining or film 103 may be any suitable film adapted for patient contact, and may or may not have an adhesive backing for securement to the skin. The film or lining 103 may overlap a peripheral portion of the cover 22. The film or lining 103 may or may not be adhesively coated, and, in some embodiments is a thin, transparent, polymeric membrane such as polyurethane, elastomeric polyester or polyethylene.


The film or lining 103 may serve to impede direct contact between the elongate wick 104 and the healthy skin “s.” The film or lining 103 may exhibit a first width “w1” between two elongate edges that is substantially greater than a second width “w2” defined by the elongate wick 104. For instance, a lining 103 having a first width “w1” of about 2 inches may provide a sufficient area to permit an elongate wick 104 having a second width “w2” of about 1 inch to rest entirely within the confines of the lining 103. The film or lining 103 may be applied to the skin “s” either prior to the application of the elongate wick 104 and the wick cover 106, or concurrently therewith.


The elongate wick 104 defines a longitudinal direction therealong between a first end 110 positioned near the aperture 24 in the cover layer 22, and a second end 112 near the remote location “r.” The elongate wick 104 is adapted for longitudinal transport of fluids therethrough. The elongate wick 104 may promote capillary action in a longitudinal direction to provide for the longitudinal transport of fluids. A cross section of individual fibers, or an arrangement of fibers may serve to transport fluids longitudinally. The elongate wick 104 may be constructed from materials suitable for use as wound filler 20. The elongate wick 104 may, for example, be constructed of hydrophobic fibers, such as continuous synthetic fibers, arranged as an elongate rope or cord. The fibers may be crimped, bulked or lofted to influence the absorptive, wicking or comfort characteristics of the elongate wick 104. U.S. Provisional Application No. 61/188,370, filed Aug. 8, 2008, the entire content of which is hereby incorporated by reference, describes various such processes and arrangements for fibers, which may be employed to construct the elongate wick 104 or the filler 20.


The elongate wick 104 may also be constructed from a three-dimensional spacer fabric. As depicted in FIG. 3, a three dimensional spacer fabric includes an upper fabric layer 104u spaced from a lower fabric layer 104l by an intermediate layer 104i of upright pile threads. The intermediate layer 104i of upright pile threads provides space between the upper and lower layers 104u and 104i through which wound fluids and atmospheric gasses may be transported.


This multi-layer arrangement offers a structural versatility, which permits the elongate wick 104 to conform to the needs of a particular patient or wound. The upright pile threads may exhibit a variety of different constructions in terms of surface structure, elasticity, diameter, length, position, number and orientation. For example, the upright pile threads may be arranged at a steep angle to provide cushioning in the event the upper and lower layers 104u and 104l are compressed together. Also, the upper and lower layers 104u and 104i may assume any particular weave or knit pattern. A ribbed knit pattern may provide flexibility in an appropriate direction to permit the wick to conform to highly contoured body areas. A variety of thicknesses, densities, compression, air permeability and softness characteristics may be provided by selecting an appropriate material and arrangement of the individual layers 104u, 104i and 104u.


An appropriate three-dimensional spacer fabric for use in elongate wick 104 is marketed under the trade name AirX—Comfort, by Tytex, Inc. of Woonsocket, R.I. In addition to offering a high MVTR and friction resistance, this product may be constructed to include a visco-elastic plastic yielding a heat-moldable structure. A heat-moldable wick 104 may be subjected to heat prior to positioning the wick 104 over lining 103 or healthy skin “s” to pre-conform the wick 104 to a particular body contour. Alternatively, visco-elastic plastics may be provided that are responsive to body heat to provide a conformable wick 104.


Alternatively, elongate wick 104 may be constructed from staple fibers, and may be arranged as woven or kitted fabrics. The fibers may be treated with antibacterial agents such as polyhexamethylene biguanide (PHMB) to decrease the incidence of infection, or other medicaments to promote healing of the wound “w.” The fibers may also include combinations of materials or chemicals to tailor the wick for specific fluid transport, comfort or other specific requirements.


The wick cover 106 has a first end 114 positioned near the aperture 24 in the cover layer and beyond the first end 110 of the elongate wick 104. A second end 116 of the wick cover 106 is positioned near the remote location “r.” The first end 114 of wick cover 106 forms a substantially fluid-tight seal with the cover layer 22, and the second end 116 of the wick cover 106 forms a substantially fluid tight seal with the lining 103 or the skin in the absence of the lining 103. The second end 114 of wick cover 106 may contact or be secured to lining 103 thereby assisting in securement of the lining relative to the subject and optionally forming an enclosure 105 between the wick cover 106 and the lining 103 substantially enclosing the a portion of the elongated wick 103 preventing exudate from contacting the skin. In the absence of a lining 103, an enclosure may be formed between the wick cover 106 and the skin “s.”


Wick cover 106 may be constructed from any of the materials used to fabricate cover layer 22. For example, wick cover 106 may be constructed of an adhesively coated, thin, transparent, polymeric membrane such as polyurethane, elastomeric polyester or polyethylene. The thickness of the wick cover 106 may, for example, be in the range of about 0.8 mils to about 1.2 mils. Thicknesses in this range may permit wick cover 106 to conform comfortably to the contours of a patient's skin surrounding the elongate wick 104, and accommodate evacuation cycles associated with an NPWT procedure. The adhesive coating should provide firm, continuous adhesion to the lining 103, the skin “s” and/or the cover layer 22 such that leak paths are not readily formed as reservoir 14 is subjected to the evacuation cycles of an NPWT treatment. As seen in FIG. 2B, wick cover 106 may also define a third width “w3,” which is substantially greater than the first width “w1” of the lining 103. This permits wick cover 106 to be adhesively secured to the skin “s” on either side of the elongate edges of the lining 103, and to an upper surface of the lining 103 as well. The adhesive should also not unduly interfere with the MVTR of the wick cover, and should peel away from the skin “s” easily when the wick cover 106 is no longer required.


An aperture 118 in the wick cover 106 facilitates fluid communication between fluid port 30 and the elongate wick 104. The fluid port 30 forms a substantially fluid tight seal with the wick cover 106 near the aperture 118 and receives fluid conduit 36. Fluid conduit 36 may be coupled to a vacuum source 50 as described above with reference to FIG. 1.


In this manner, fluids such as wound exudates and atmospheric gasses may be drawn from the reservoir 14, through the aperture 24 in the cover layer 22, and into the first end 110 of the elongate wick 104. The fluids are transported longitudinally through the wick 104 under the influence of the reduced pressure and the fluid transport properties of the wick 104 to the second end 112 of the wick 104 near the remote location “r.” The fluids may then be removed from the bridging dressing 102 through the fluid port 30. Since the wick 104 and the wick cover 106 are generally more flexible and conformable to the contours of the patient's body, and also to the movements of the patient than fluid port 30, these components of bridging dressing 102 are typically more comfortable positioned adjacent to the wound “w.”


Referring now to FIG. 4A, an alternate embodiment of the disclosure permits fluid communication between the fluid conduit 36 and the second end 112 of the wick 104 near the remote location “r” to be established without the use of a flanged fluid port. A wick cover 106a includes a second end 116a devoid of an aperture for the attachment of a fluid port. Rather, the wick cover 106a forms a substantially fluid tight seal with the fluid conduit 36 and the lining 103 surrounding the remote location “r.” This configuration allows fluid conduit 36 to be placed comfortably at the remote location “r” rather than near the wound “w.” Since the fluid conduit 36 may be generally less conformable or more rigid than the wick 104 and the wick cover 106a, placement of the fluid conduit 36 remote from the wound “w” may be more comfortable than adjacent the wound “w.”


Referring now to FIG. 4B, another alternate embodiment of the disclosure permits fluid communication between the elongate wick 104 and a reservoir 104a over the wound “w.” The wick cover 106a includes a first end 114a extending into the reservoir 14a. Cover layer 22b may form a substantially fluid-tight seal with an upper surface of the wick cover 106a such that an aperture 24a in the wick cover 106a permits fluid communication between the reservoir 14a and the elongate wick 104. This configuration permits application of the lining 103, the wick 104 and the wick cover 106a prior to the application of the cover layer 22b. Various other configurations of similar components may also provide a bridge for a wound dressing.


Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity or understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Claims
  • 1. A composite wound dressing apparatus comprising: a cover layer for defining a reservoir over a wound in which a negative pressure may be maintained by forming a substantially fluid-tight seal around the wound, the cover layer including an aperture therein through which fluids may be extracted from the reservoir;an elongate wick having a first end and a second end, wherein the first end is configured to be in fluid communication with the reservoir through the aperture in the cover layer, and the second end is configured to be disposed remotely with respect to the aperture in the cover layer, the elongate wick comprising a three-dimensional spacer fabricsuch that the elongate wick only partially extends over the cover layer and a portion of the elongate wick is not above the cover layer;a flexible wick cover extending over the elongate wick and configured for extending partially over the cover layer, the wick cover having a first end configured to be positioned over the aperture in the cover layer and a second end configured to be disposed at a location remote from the wound and the cover layer such that the wick cover and the cover layer do not have substantially similar dimensions, the wick cover extending between the first end configured to be positioned over the aperture in the cover layer and the second end configured to be disposed at the location remote from the wound, the first end of the wick cover configured for forming a substantially fluid tight seal over the aperture in the cover layer, the second end of the wick cover cover including an aperture therein through which fluids may be extracted from the elongate wick, the wick cover having an adhesive coating foralong a length of the wick cover extending between the first and second ends, the adhesive coating for establishing athe substantially fluid tight seal over the aperture in the cover layer and with thea skin surface disposed remotelyat the location remote from the wound cover; anda fluid port coupled to the wick cover and in fluid communication with the second end of the elongate wick through the aperture in the wick cover.
  • 2. The apparatus according to claim 1, further comprising a skin covering positioned beneath at least a portion of the elongate wick to impede direct contact of the elongate wick with the skin surface.
  • 3. The apparatus according to claim 2, wherein the skin covering defines a first width, the elongate wick defines a second width and the wick cover defines a third width, the third width of the wick cover substantially greater than the first width of the skin covering.
  • 4. The apparatus according to claim 3, wherein the first width is about 2 inches, the second width is about one inch, and the third width is about 3 inches.
  • 5. The apparatus according to claim 1, wherein the fluid port is configured to receive a fluid conduit.
  • 6. The apparatus according to claim 2, wherein the fluid port includes a flange coupled to an underside of the wick cover.
  • 7. The apparatus according to claim 1, wherein the elongate wick is treated with an antimicrobial agent.
  • 8. The apparatus according to claim 7, wherein the antimicrobial agent is polyhexamethylene biguanide.
  • 9. A negative pressure wound therapy apparatus, comprising: a cover layer disposed overfor defining a reservoir inover a wound in which a negative pressure may be maintained;an elongate wick having a first end and a second end, wherein the first end is configured to be in fluid communication with the reservoir, and the second end is configured to be at a location disposed remotely from the wound, the elongate wick comprising a three-dimensional spacer fabricsuch that the elongate wick only partially extends over the cover layer and a portion of the elongate wick is not above the cover layer;a wick cover disposed over the elongate wick and configured for extending partially over the cover layer, the wick cover having a first end configured to be positioned over an aperture in the cover layer and a second end configured to be disposed at the location disposed remotely from the wound and the cover layer such that the wick cover and the cover layer do not have substantially similar dimensions, the wick cover extending between the first end configured to be positioned over the aperture in the cover layer and the second end configured to be disposed at the location remote from the wound cover, the first end of the wick cover configured for forming a substantially fluid tight seal withover the aperture in the cover layer, the second end of the wick cover including an aperture in fluid communication with the elongate wick,an adhesive coating for the wick cover to establish aprovided along a length of the wick cover, the adhesive coating for establishing the substantially fluid tight seal over the aperture in the cover layer and with thea skin surface at the location disposed remotely from the wound; anda vacuum source configured to be in fluid communication with the reservoir.
  • 10. The apparatus according to claim 1, including a vacuum source in fluid communication with the fluid port, the vacuum source suitable for generating the negative pressure in the reservoir.
  • 11. The apparatus according to claim 9 wherein the vacuum source is in fluid communication with the reservoir through the elongate wick.
  • 12. The apparatus according to claim 11 including a fluid port mounted to the wick cover, and wherein the vacuum source is in fluid communication with the reservoir through the fluid port.
  • 13. The apparatus according to claim 11 wherein the elongate wick comprises polyhexamethylene biguanide.
  • 14. The apparatus according to claim 11 wherein the elongate wick comprises a three dimensional spacer fabric comprisescomprising an upper fabric layer, a lower fabric layer, and an intermediate layer of pile threads between the upper fabric layer and the lower fabric layer.
  • 15. The apparatus according to claim 11 wherein the elongate wick comprises hydrophobic fibers.
  • 16. The apparatus according to claim 2, wherein at least a portion of the skin covering is interposed between the skin surface and the wick cover.
  • 17. A negative pressure wound therapy apparatus comprising: a main wound dressing portion comprising a cover layer for defining a vacuum reservoir over a wound in which negative pressure may be maintained; anda bridging dressing portion configured to provide fluid communication between the vacuum reservoir and a remote location from the main wound dressing portion, the bridging dressing portion comprising: a lower film layer having a first width between two elongate edges of the lower film layer;an elongate wick having a second width between two elongate edges of the elongate wick, the elongate wick configured to be positioned over the lower film layer and having a length that spans a distance between the main wound dressing portion and the remote location, wherein the elongate wick is configured to be in fluid communication with the vacuum reservoir of the main wound dressing portion; andan upper film layer having a third width between two elongate edges of the upper film layer, the upper film layer configured to be positioned over the elongate wick and configured to be partially over the cover layer of the main wound dressing portion;wherein the second width is less than a width of the main dressing portion;wherein the elongate wick is in contact with the upper film layer and the lower film layer along an entire length of the elongate wick; andwherein at least one of the upper film layer and the lower film layer has an adhesive coating provided thereon at the remote location and establishing a substantially fluid tight seal with a skin surface disposed at the remote location from the main wound dressing portion.
  • 18. The apparatus according to claim 17, wherein the cover layer includes an aperture therein through which negative pressure may be applied to the vacuum reservoir.
  • 19. The apparatus according to claim 18, wherein the bridging dressing portion is positioned partially over the cover layer.
  • 20. The apparatus according to claim 19, wherein the upper film layer has an adhesive coating for establishing a substantially fluid tight seal over the aperture in the cover layer.
  • 21. The apparatus according to claim 17, wherein the main wound dressing portion comprises a contact layer configured to be positioned over the wound and a filler between the contact layer and the cover layer.
  • 22. The apparatus according to claim 17, further comprising a fluid port coupled to the upper film layer.
  • 23. The apparatus according to claim 17, wherein the elongate wick comprises a three-dimensional spacer fabric.
  • 24. The apparatus according to claim 17, wherein the upper film layer is secured to the lower film layer forming an enclosure between the upper film layer and the lower film layer substantially enclosing the elongate wick.
  • 25. The apparatus according to claim 17, wherein the second width is less than the first width or the third width.
  • 26. The apparatus according to claim 17, wherein the cover layer of the main portion and the upper film layer of the bridging portion comprise the same material.
  • 27. A negative pressure wound therapy apparatus comprising: a wound dressing comprising a cover layer having an aperture; andan elongate bridge having a first end and a second end, the first end configured to be positioned over the aperture in the wound dressing and the second end configured to be disposed at a remote location away from the wound dressing, wherein the elongate bridge comprises: an upper film layer,an elongate wick comprising a three-dimensional fabric material positioned beneath the upper film layer, the elongate wick configured to be positioned over the aperture in the wound dressing at the first end of the elongate bridge; anda lower film layer positioned beneath the elongate wick and secured to the upper film layer;wherein at least the elongate wick extends from the aperture in the wound dressing to the remote location;wherein the elongate wick is in contact with the upper film layer and the lower film layer along an entire length of the elongate wick;wherein the first end of the elongate bridge is provided with an adhesive coating configured to establish a substantially fluid tight seal over the aperture in the wound dressing and that adheres the first end of the elongate bridge to the cover layer; andwherein the lower film layer has an adhesive coating for establishing a substantially fluid tight seal with a skin surface disposed remotely from the wound dressing.
  • 28. The apparatus according to claim 27, wherein the lower film layer is secured to the upper film layer forming an enclosure between the upper film layer and the lower film layer substantially enclosing the elongate wick.
  • 29. The apparatus according to claim 27, wherein the three-dimensional spacer fabric comprises: a lower fabric layer;an intermediate layer of upright pile threads; andan upper fabric layer spaced from the lower fabric layer by the intermediate layer of upright pile threads.
  • 30. The apparatus according to claim 29, wherein one or both of the lower fabric layer and the upper fabric layer comprises a knit or weave pattern.
  • 31. The apparatus according to claim 27, wherein the elongate wick comprises hydrophobic fibers.
  • 32. The apparatus according to claim 27, wherein the elongate wick comprises a plurality of fibers that are crimped, bulked or lofted.
  • 33. The apparatus according to claim 27, wherein the lower film layer has a first width, the elongate wick has a second width, and the upper film layer has a third width, wherein the second width is less than the first width or the third width.
  • 34. The apparatus according to claim 27, further comprising a fluid port at the second end of the elongate bridge for removal of fluids from the elongate bridge.
  • 35. The apparatus according to claim 34, further comprising an aperture in the upper film layer, wherein the fluid port is sealed to the upper film layer over the aperture in the upper film layer.
  • 36. The apparatus according to claim 27, wherein the wound dressing comprises a contact layer and a filler positioned between the contact layer and the cover layer.
  • 37. The apparatus according to claim 27, further comprising a fluid conduit for connecting the second end of the elongate bridge to a vacuum source.
  • 38. The apparatus according to claim 27, further comprising a vacuum source configured to apply vacuum to the elongate bridge.
  • 39. The apparatus according to claim 27, further comprising a collection canister for containing wound fluids removed from a wound through the elongate bridge.
  • 40. The apparatus according to claim 1, wherein the elongate wick comprises a three dimensional spacer fabric.
US Referenced Citations (260)
Number Name Date Kind
3367332 Groves Feb 1968 A
3486504 Austin, Jr. Dec 1969 A
3568675 Harvey Mar 1971 A
3572340 Lloyd et al. Mar 1971 A
3712298 Snowdon et al. Jan 1973 A
3809086 Schachet et al. May 1974 A
3874387 Barbieri Apr 1975 A
4080970 Miller Mar 1978 A
4112947 Nehring Sep 1978 A
4112949 Rosenthal et al. Sep 1978 A
4136696 Nehring Jan 1979 A
4266545 Moss May 1981 A
4382441 Svedman May 1983 A
4524064 Nambu Jun 1985 A
4605399 Weston et al. Aug 1986 A
4743232 Kruger May 1988 A
4921492 Schultz et al. May 1990 A
4969880 Zamierowski Nov 1990 A
4990137 Graham Feb 1991 A
4997438 Nipper Mar 1991 A
5071409 Rosenberg Dec 1991 A
5100395 Rosenberg Mar 1992 A
5100396 Zamierowski Mar 1992 A
5106629 Cartmell et al. Apr 1992 A
5141503 Sewell, Jr. Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5152757 Eriksson Oct 1992 A
5160322 Scheremet et al. Nov 1992 A
5176663 Svedman et al. Jan 1993 A
5178157 Fanlo Jan 1993 A
5180375 Feibus Jan 1993 A
5195977 Pollitt Mar 1993 A
5261893 Zamierowski Nov 1993 A
5263922 Sova et al. Nov 1993 A
5437683 Neumann et al. Aug 1995 A
D364679 Heaton et al. Nov 1995 S
5484427 Gibbons Jan 1996 A
5527293 Zamierowski Jun 1996 A
5536233 Khouri Jul 1996 A
5549584 Gross Aug 1996 A
5588958 Cunningham et al. Dec 1996 A
5599289 Castellana Feb 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5678564 Lawrence et al. Oct 1997 A
5701917 Khouri Dec 1997 A
5733305 Fleischmann Mar 1998 A
5795584 Totakura et al. Aug 1998 A
5840049 Tumey et al. Nov 1998 A
5911222 Lawrence et al. Jun 1999 A
5944703 Dixon et al. Aug 1999 A
6010524 Fleischmann Jan 2000 A
6071267 Zamierowski Jun 2000 A
6117111 Fleischmann Sep 2000 A
6135116 Vogel et al. Oct 2000 A
D434150 Tumey et al. Nov 2000 S
6142982 Hunt et al. Nov 2000 A
6174306 Fleischmann Jan 2001 B1
6203563 Fernandez Mar 2001 B1
6261276 Reitsma Jul 2001 B1
6325788 McKay Dec 2001 B1
6345623 Heaton et al. Feb 2002 B1
6348423 Griffiths et al. Feb 2002 B1
6398767 Fleischmann Jun 2002 B1
6406447 Thrash et al. Jun 2002 B1
6420622 Johnston et al. Jul 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6500112 Khouri Dec 2002 B1
D469175 Hall et al. Jan 2003 S
D469176 Hall et al. Jan 2003 S
6520982 Boynton et al. Feb 2003 B1
6553998 Heaton et al. Apr 2003 B2
D475134 Randolph May 2003 S
6557704 Randolph May 2003 B1
D478659 Hall et al. Aug 2003 S
6607495 Skalak et al. Aug 2003 B1
6626891 Ohmstede Sep 2003 B2
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6695824 Howard et al. Feb 2004 B2
D488558 Hall Apr 2004 S
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6800074 Henley et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6887228 McKay May 2005 B2
6887263 Bleam et al. May 2005 B2
6936037 Bubb et al. Aug 2005 B2
6942633 Odland Sep 2005 B2
6942634 Odland Sep 2005 B2
6951553 Bubb et al. Oct 2005 B2
6960181 Stevens Nov 2005 B2
6979324 Bybordi et al. Dec 2005 B2
D515701 Horhota et al. Feb 2006 S
6994702 Johnson Feb 2006 B1
7004915 Boynton et al. Feb 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7037254 O'Connor et al. May 2006 B2
7052167 Vanderschuit May 2006 B2
7070584 Johnson et al. Jul 2006 B2
7077832 Fleischmann Jul 2006 B2
7108683 Zamierowski Sep 2006 B2
7117869 Heaton et al. Oct 2006 B2
7128719 Rosenberg Oct 2006 B2
7128735 Weston Oct 2006 B2
7144390 Hannigan et al. Dec 2006 B1
7169151 Lytinas Jan 2007 B1
7182758 McCraw Feb 2007 B2
7195624 Lockwood et al. Mar 2007 B2
7198046 Argenta et al. Apr 2007 B1
7214202 Vogel et al. May 2007 B1
7216651 Argenta et al. May 2007 B2
D544092 Lewis Jun 2007 S
7273054 Heaton et al. Sep 2007 B2
7276051 Henley et al. Oct 2007 B1
7279612 Heaton et al. Oct 2007 B1
7316672 Hunt et al. Jan 2008 B1
D565177 Locke et al. Mar 2008 S
7338482 Lockwood et al. Mar 2008 B2
7351250 Zamierowski Apr 2008 B2
7361184 Joshi Apr 2008 B2
7381211 Zamierowski Jun 2008 B2
7381859 Hunt et al. Jun 2008 B2
7396345 Knighton et al. Jul 2008 B2
7410495 Zamierowski Aug 2008 B2
7413570 Zamierowski Aug 2008 B2
7413571 Zamierowski Aug 2008 B2
7422576 Boynton et al. Sep 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7485112 Karpowicz et al. Feb 2009 B2
7503910 Adahan Mar 2009 B2
7531711 Sigurjonsson et al. May 2009 B2
7534927 Lockwood et al. May 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7645269 Zamierowski Jan 2010 B2
7651484 Heaton et al. Jan 2010 B2
7670323 Hunt et al. Mar 2010 B2
7678102 Heaton Mar 2010 B1
7686785 Boehringer et al. Mar 2010 B2
7794438 Henley et al. Sep 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7862718 Doyen et al. Jan 2011 B2
7880050 Robinson et al. Feb 2011 B2
7942866 Radl et al. May 2011 B2
8021347 Vitaris et al. Sep 2011 B2
8083712 Biggie et al. Dec 2011 B2
8133211 Cavanaugh, II et al. Mar 2012 B2
8142419 Heaton et al. Mar 2012 B2
8147468 Barta et al. Apr 2012 B2
8148595 Robinson et al. Apr 2012 B2
8152785 Vitaris Apr 2012 B2
8158844 McNeil Apr 2012 B2
8162907 Heagle Apr 2012 B2
8168848 Lockwood et al. May 2012 B2
8188331 Barta et al. May 2012 B2
8202261 Kazala, Jr. et al. Jun 2012 B2
8241261 Randolph et al. Aug 2012 B2
8246606 Stevenson et al. Aug 2012 B2
8257327 Blott et al. Sep 2012 B2
8267908 Coulthard Sep 2012 B2
8298200 Vess et al. Oct 2012 B2
8376972 Fleischmann Feb 2013 B2
8382731 Johannison Feb 2013 B2
8469915 Johannison et al. Jun 2013 B2
8506554 Adahan Aug 2013 B2
8545466 Andresen et al. Oct 2013 B2
8734410 Hall et al. May 2014 B2
9017302 Vitaris et al. Apr 2015 B2
9033942 Vess May 2015 B2
9227000 Fink et al. Jan 2016 B2
9474654 Heagle et al. Oct 2016 B2
20010020145 Satterfield et al. Sep 2001 A1
20010031943 Urie Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20020016577 Ohmstede Feb 2002 A1
20020143286 Tumey Oct 2002 A1
20020151836 Burden Oct 2002 A1
20030093041 Risk, Jr. et al. May 2003 A1
20030208149 Coffey Nov 2003 A1
20030212357 Pace Nov 2003 A1
20030212359 Butler Nov 2003 A1
20030219469 Johnson et al. Nov 2003 A1
20040006319 Lina et al. Jan 2004 A1
20040030304 Hunt et al. Feb 2004 A1
20040039415 Zamierowski Feb 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040073151 Weston Apr 2004 A1
20040093026 Weidenhagen et al. May 2004 A1
20040122434 Argenta et al. Jun 2004 A1
20040193218 Butler Sep 2004 A1
20040241213 Bray Dec 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20050010153 Lockwood et al. Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050070835 Joshi Mar 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050085795 Lockwood et al. Apr 2005 A1
20050101940 Radl et al. May 2005 A1
20050177190 Zamierowski Aug 2005 A1
20050182445 Zamierowski Aug 2005 A1
20050222527 Miller et al. Oct 2005 A1
20050222544 Weston Oct 2005 A1
20050261642 Weston Nov 2005 A1
20050261643 Bybordi et al. Nov 2005 A1
20060015087 Risk, Jr. et al. Jan 2006 A1
20060025727 Boehringer et al. Feb 2006 A1
20060039742 Cable, Jr. et al. Feb 2006 A1
20060041247 Petrosenko et al. Feb 2006 A1
20060079852 Bubb et al. Apr 2006 A1
20060100586 Karpowicz et al. May 2006 A1
20060100594 Adams et al. May 2006 A1
20060116620 Oyaski Jun 2006 A1
20070014837 Johnson et al. Jan 2007 A1
20070021697 Ginther et al. Jan 2007 A1
20070027414 Hoffman et al. Feb 2007 A1
20070032754 Walsh Feb 2007 A1
20070032755 Walsh Feb 2007 A1
20070032778 Heaton et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070066946 Haggstrom et al. Mar 2007 A1
20070078366 Haggstrom et al. Apr 2007 A1
20080082035 Evans Apr 2008 A1
20080167593 Fleischmann Jul 2008 A1
20080195017 Robinson et al. Aug 2008 A1
20090012501 Boehringer et al. Jan 2009 A1
20090124988 Coulthard May 2009 A1
20090126103 Dietrich et al. May 2009 A1
20090131892 Karpowicz et al. May 2009 A1
20090157016 Carmeli Jun 2009 A1
20090227968 Vess Sep 2009 A1
20090227969 Jaeb Sep 2009 A1
20090234307 Vitaris Sep 2009 A1
20090264837 Adahan Oct 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299249 Wilkes et al. Dec 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20090299256 Barta et al. Dec 2009 A1
20090299257 Long et al. Dec 2009 A1
20090299303 Seegert Dec 2009 A1
20090299307 Barta et al. Dec 2009 A1
20090299308 Kazala et al. Dec 2009 A1
20090299340 Kazala et al. Dec 2009 A1
20090299341 Kazala et al. Dec 2009 A1
20090299342 Cavanaugh, II et al. Dec 2009 A1
20090312728 Randolph et al. Dec 2009 A1
20100069850 Fabo Mar 2010 A1
20100069885 Stevenson et al. Mar 2010 A1
20100160901 Hu et al. Jun 2010 A1
20110125113 Adahan May 2011 A1
20110130712 Topaz Jun 2011 A1
20120302976 Locke et al. Nov 2012 A1
20150073358 Jaeb et al. Mar 2015 A1
Foreign Referenced Citations (74)
Number Date Country
674837 Jan 1997 AU
41 11 122 Apr 1993 DE
295 04 378 Oct 1995 DE
43 06 478 Dec 2008 DE
0 020 662 Jul 1984 EP
0 358 302 Mar 1990 EP
0 392 640 Jun 1995 EP
0 441 418 Jul 1995 EP
0 777 504 Oct 1998 EP
1 169 071 Jan 2002 EP
0 751 757 Feb 2002 EP
0 853 950 Oct 2002 EP
1 487 389 Dec 2004 EP
0 982 015 Aug 2006 EP
1 905 465 Jan 2010 EP
2 319 550 May 2011 EP
1 578 477 Sep 2011 EP
2 413 858 Feb 2012 EP
1 660 000 Oct 2012 EP
2 545 946 Mar 2013 EP
2 490 637 Jan 2014 EP
2 051 675 Jun 2014 EP
1 549 756 Mar 1977 GB
2 195 255 Apr 1988 GB
2 235 877 Mar 1991 GB
2 307 180 Jun 2000 GB
2 336 546 Jun 2000 GB
2 344 531 Jun 2000 GB
1762940 Jan 1989 SU
WO 8001139 Jun 1980 WO
WO 8002182 Oct 1980 WO
WO 8401904 May 1984 WO
WO 8905133 Jun 1989 WO
WO 9011795 Oct 1991 WO
WO 9219313 Nov 1992 WO
WO 9605873 Feb 1996 WO
WO 03057307 Jul 2003 WO
WO 03101508 Dec 2003 WO
WO 2005009488 Feb 2005 WO
WO 2005016179 Feb 2005 WO
WO 2005061025 Jul 2005 WO
WO 2006015599 Feb 2006 WO
WO 2007006306 Jan 2007 WO
WO 2007016590 Feb 2007 WO
WO 2007019038 Feb 2007 WO
WO 2007041642 Apr 2007 WO
WO 2007085396 Aug 2007 WO
WO 2007092397 Aug 2007 WO
WO 2007095180 Aug 2007 WO
WO 2007106590 Sep 2007 WO
WO 2007106591 Sep 2007 WO
WO 2008008032 Jan 2008 WO
WO 2008012278 Jan 2008 WO
WO 2008027449 Mar 2008 WO
WO 2008043067 Apr 2008 WO
WO 2008100440 Aug 2008 WO
WO 2008100446 Aug 2008 WO
WO 2008131895 Nov 2008 WO
WO 2008135997 Nov 2008 WO
WO 2008141470 Nov 2008 WO
WO 2009068665 Jun 2009 WO
WO 2009086580 Jul 2009 WO
WO 2009088925 Jul 2009 WO
WO 2009111655 Sep 2009 WO
WO 2009137194 Nov 2009 WO
WO 2009140376 Nov 2009 WO
WO 2009141820 Nov 2009 WO
WO 2009145894 Dec 2009 WO
WO 2010014177 Feb 2010 WO
WO 2010033769 Mar 2010 WO
WO 2010042240 Apr 2010 WO
WO 2010051073 May 2010 WO
WO 2010059730 May 2010 WO
WO 2010078166 Jul 2010 WO
Non-Patent Literature Citations (31)
Entry
US 6,216,701, 04/2001, Heaton et al. (withdrawn)
US 7,186,244, 03/2007, Hunt et al. (withdrawn)
B. M. Kostiuchenok, et al., “The Vacuum Effect in the Surgical Treatment of Purulent Wounds,” Russian Journal: Vestnik Khirurgii, Sep. 1986 (18-21).
Y.N. Usupov, et al., “Active Wound Drainage,” Russian Journal: Vestnik Khirugii, Apr. 1987 (42-45).
N.A. Bagautdinov (Kazan), “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” UDC 616-002.36 (94-96).
Yu A. Davydov, et al., “Bacteriological and Cytological Assessment of Vacuum Therapy of Purulent Wounds”, Vestnik Khirurgii, Oct. 1988 (48-52).
Göran Sandén, M.D., et al., “Staphylococcal Wound Infection in the Pig: Part II. Innoculation, Quantification of Bacteria, and Reproducibility,” Annals of Plastic Surgery, vol. 23, No. 3, Sep. 1989, (219-223).
Arnljots, et al., “Irrigation Treatment in Split-thickness Skin Grafting of Intractable Leg Ulcers,” Scand J Plast Reconstr Surg 19: 211-213, 1985.
Bagautdinov, N.A., “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” in Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye. Volkov et al. (Chuvashia State University, Cheboksary, USSR 1986) pp. 94-96 (with English translation).
European Examination Report, re EPO Application No. 09839009.9, dated Oct. 12, 2016.
Meyer, MD., et al., “In Surgery, Medicine and the Specialties A Manual of its Practical Application”, Bier's Hyperemic Treatment, Second Revised Edition, W.B. Saunders Company, 1909.
Sandén, Göran MD., et al., “Staphylococcal Wound Infection in the Pig: Part II. Innoculation, Quantification of Bacteria, and Reproducibility,” Annals of Plastic Surgery, vol. 23, No. 3, Sep. 1989, (219-223).
Jeter, Katherine F., et al., “Managing Draining Wounds and Fistulae: New and Established Methods”, Chronic Wound Care, 1990, pp. 240-246.
Chariker, M. E. et al. (eds), “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction Wound Drainage,” Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Yu A. Davydov, et al., “Concepts for Clinical Biological Management of the Wound Process in the Treatment of Purulent Wounds Using Vacuum Therapy,” Vestnik Khirugii, Feb. 1991, 132-135).
Chardack, et al., “Experimental studies on Synthetic Substitutes for Skin and Their Use in the Treatment of Burns,” vol. 155, No. 1 (128-136).
Gorica Zivadinovic, et al., “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Conference Papers of the 5th Timok Medical Days, Majdanpek, 1986 (161-164).
Ryosuke Fujimoro, M.D., et al., “Sponge Fixation Method for Treatment of Early Scars,” From the Department of Dermatology in the Faculty Medicine, Kyoto University, vol. 42, No. 4, Oct. 1968 (323-326).
W. Fleischmann, et al., Vacuum Sealing: Indication, Technique and Results, Emr J Orthop Surg Tramatol (1995) 5:37-40.
Sherry Stoll, “Energetic Remedies—Cupping: Healing Within a Vacuum,” https://www.suite101.com/article.cfm/energetic)remedies/74531, Apr. 13, 2005.
Mulder, G.D, et al., “Clinicians' Pocket Guide to Chronic Wound Repair,” Wound Healing Publications Second Edition, 1991.
Yu A. Davydov, et al., “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis,” Russian Journal: Vesnik Khirurgii, Sep. 1986 (66-70).
W. Fleischmann, “Vacuum Sealing for Treatment of Problematical Wounds”, University Surgical Clinic and Polyclinic—Accident Surgery Department, WundForum Spezial—IHW 94.
Björn, et al., “Irrigation Treatment in Split-thickness Skin Grafting of Intractable Leg Ulcers,” Scand J Plast Reconstr Surg 19: 211-213, 1985.
Paul Svedman, et al., “Staphylococcal Wound Infection in the Pig: Part I. Course,” Annals of Plastic Surgery, vol. 23, No. 3, Sep. 1989 (212-218).
Paul Svedman, “A Dressing Allowing Continuous Treatment of a Biosurface,” IRCS Medical Science: Biomedical Technology; Clinical Medicine; Surgery and Transplantation, 7, 221 (1979).
Paul Svedman, “Irrigation Treatment of Leg Ulcers,” The Lancet, Sep. 3, 1983 (532-534).
H. Teder, et al., “Continuous Wound Irrigation in the Pig,” Journal of Investigative Surgery, vol. 3 (399-407).
P. Svedman, “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation,” Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986 (125-133).
Yu A. Davydov, et al., “Vacuum Therapy in treatment of Acute Purulent Diseases of Soft Tissues and Purulent Wounds,” Vestnik Khirurgii, (Surgeon's Herald), Medicine Publishers, 1986.
International Search Report Application No. PCT/US09/046987 dated Aug. 6, 2009.
Reissues (1)
Number Date Country
Parent 12356246 Jan 2009 US
Child 14261296 US